Abstract
Introduction: A major public health problem is the emergence of anti-gram-negative antimicrobial resistance worldwide. Cefiderocol is a new agent targeting Gram-negative bacteria, including strains with resistance to carbapenems.
 Aim of the study: Analysis of the efficiency of cefiderocol in the treatment of infections caused by gram-negative bacteria, the drug's mechanism of action and pharmacokinetics and pharmacodynamics of the drug.
 Material and Methods: Search of the PubMed database using the following keywords: cefiderocol, resistance, gram negative bacteria. Only full-length articles were taken into consideration.
 Results: The studies show that cefiderocol is active against Enterobacteriaceae, P. aeruginosa, B. cepacia and A. baumannii and effective in the treatment of pneumonia in both non-ventilated and ventilated patients. Moreover, it has been used in the treatment of sepsis as a rescue therapy.
 Conclusion: Cefiderocol is an effective treatment for infections caused by gram-negative bacteria. However, more research is needed to learn more about the use of this drug, side effects and resistance mechanisms.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
